We report the first successful production of PRSV-P resistant backcross (BC) papaya plants following intergeneric hybridisation between C. papaya and a Vasconcellea species after 50 years of reports on unsuccessful attempts. This follows our previous reports of PRSV-P resistant F 1 hybrids developed by intergeneric hybridisation between C. papaya and V. quercifolia. One PRSV-P resistant BC 1 (BC 1 ) plant was produced after 114,839 seeds were dissected from 940 fruits. The seeds yielded 1,011 embryos and 733 germinated in vitro from which 700 developed into plantlets that were screened in a glasshouse and in the field under high disease pressure and exposure to inoculation by viruliferous aphids. From the PRSV-P resistant backcross 1 (BC 1 ) male plant, 1465 plants [137 BC 2 , 546 SbC 2 (BC2 sib-crosses), 147 BC 3 , 379 SbC 3 and 256 BC 4 ] were grown from seed and inoculated with PRSV-P and virus resistant BC 3 and BC 4 plants were selected from these generations. Presence or absence of virus was confirmed by ELISA serological tests. BC plants generally developed mild symptoms of PRSV-P after periods ranging from 5 to 18 months in the field but many showed the ability to produce new growth free of symptoms. All control plants developed severe symptoms after 3 months in the field. Some BC 3 and BC 4 plants were free from viral infection after 18 months in the field. Subsequently they developed very mild symptoms on their leaves and a few ringspots on their fruit. They continued to grow vigorously and produce fruit for 3 years under high disease pressure provided by the infected controls and other susceptible plants. Good quality marketable fruit were produced on these plants. Application of these results should lead to restoration of the papaya industry in virus-infested regions of the Philippines and worldwide.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.